Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer
- PMID: 17496199
- DOI: 10.1182/blood-2007-03-081133
Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer
Abstract
Signal transducer and activator of transcription 3 (Stat3) is implicated in the pathogenesis of many malignancies and essential for IL-6-dependent survival and growth of multiple myeloma cells. Here, we demonstrate that the gene encoding oncogenic microRNA-21 (miR-21) is controlled by an upstream enhancer containing 2 Stat3 binding sites strictly conserved since the first observed evolutionary appearance of miR-21 and Stat3. MiR-21 induction by IL-6 was strictly Stat3 dependent. Ectopically raising miR-21 expression in myeloma cells in the absence of IL-6 significantly reduced their apoptosis levels. These data provide strong evidence that miR-21 induction contributes to the oncogenic potential of Stat3.
Similar articles
-
BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription.Oncogene. 2006 Nov 23;25(55):7297-304. doi: 10.1038/sj.onc.1209711. Epub 2006 May 29. Oncogene. 2006. PMID: 16732314
-
Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.Blood. 2004 Jan 1;103(1):242-51. doi: 10.1182/blood-2003-04-1048. Epub 2003 Sep 11. Blood. 2004. PMID: 12969979
-
Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.BMC Cancer. 2012 Jul 28;12:318. doi: 10.1186/1471-2407-12-318. BMC Cancer. 2012. PMID: 22838736 Free PMC article.
-
Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells.Oncogene. 2009 Aug 6;28(31):2784-95. doi: 10.1038/onc.2009.142. Epub 2009 Jun 8. Oncogene. 2009. PMID: 19503092
-
MicroRNA-21 and multiple myeloma: small molecule and big function.Med Oncol. 2014 Aug;31(8):94. doi: 10.1007/s12032-014-0094-5. Epub 2014 Jul 1. Med Oncol. 2014. PMID: 24981236 Review.
Cited by
-
MiRNAs in primary cutaneous lymphomas.Cell Prolif. 2015 Jun;48(3):271-7. doi: 10.1111/cpr.12179. Epub 2015 Mar 3. Cell Prolif. 2015. PMID: 25736784 Free PMC article. Review.
-
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.Blood. 2012 Nov 8;120(19):3958-67. doi: 10.1182/blood-2012-01-401794. Epub 2012 Sep 14. Blood. 2012. PMID: 22983447 Free PMC article.
-
miRNA-regulated gene expression differs in celiac disease patients according to the age of presentation.Genes Nutr. 2015 Sep;10(5):482. doi: 10.1007/s12263-015-0482-2. Epub 2015 Aug 2. Genes Nutr. 2015. PMID: 26233308 Free PMC article.
-
MicroRNAs: New Players in Multiple Myeloma.Front Genet. 2011 May 24;2:22. doi: 10.3389/fgene.2011.00022. eCollection 2011. Front Genet. 2011. PMID: 22303318 Free PMC article.
-
MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.Oncotarget. 2016 Dec 20;7(51):84017-84029. doi: 10.18632/oncotarget.12401. Oncotarget. 2016. PMID: 27705947 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous